Raymond James analyst Robert Dodd downgrades Blackstone Secured (NYSE:BXSL) from Market Perform to Underperform.
JMP Securities Maintains Market Outperform on ProQR Therapeutics, Lowers Price Target to $5
JMP Securities analyst Jonathan Wolleben maintains ProQR Therapeutics (NASDAQ:PRQR) with a Market Outperform and lowers the price target from $8 to $5.